Amolyt Pharma is a biopharmaceutical company focused on developing treatments for hypoparathyroidism, a rare endocrine disorder. The company is developing eneboparatide, a novel parathyroid hormone receptor 1 (PTHR1) agonist, which has demonstrated promising results in clinical trials.

Thierry Abribat

Amolyt Pharma

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.

Adocia SA

Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Neovacs S.A.

Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.

Metric
Company Name	Amolyt Pharma	Adocia SA	Biotech 365	Neovacs S.A.
Symbol		ADOC		ALNEV
MSH ID	COM:AMOLYTPHARMA	COM:ADOCIA	COM:BIOTECH-365	COM:NEOVACS
Market	PRIVATE	STOCKS	PRIVATE	STOCKS
Sector	8	Healthcare	Financial Services & Finance	Healthcare
Industry	Healthcare & Health Services	Biotechnology	Biotechnology Business Services	Biotechnology
Country	FR	FR	FR	FR
Stage	Series	Post-IPO Debt		Post-IPO Debt
Employee Count	61	78		22
Website	amolytpharma.com	adocia.com	biotech-365.com	neovacs.com
LinkedIn	amolytpharma	adocia		neovacs
Founders

Metric
Market Cap		100.30M		52.99K
Enterprise Value
Monthly Web Traffic	539	521	68
Web Traffic Growth	-0.86	-0.54	-0.57
Valuation
Raised Capital	138.63M	6.96M		4.77M

Metric
Revenue	2.27M	563.41K
Revenue (LTM)
Revenue (NTM)
Gross Profit	-18.95M	-7.13M
EBITDA	-18.09M	-7.12M
Operating Income	-18.61M	-7.30M
Net Income	-22.35M	-9.24M
EPS	-2.02	-0.00
Diluted EPS	-2.02	-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-2.44	-9.71
Operating Profit Margin	-2.49	-12.95
EBITDA Margin	-7.96	-12.64
Net Profit Margin	-2.76	-16.39
Return on Equity	3.60	-0.12
Return on Assets	-1.08	-0.11
Return on Capital Employed	4.03	-0.14

COM:AMOLYTPHARMA

Amolyt Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-11.60
P/B Ratio	-6.17
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	35.40	5.78
EV Multiple	-2.91	-0.04

Metric
Days Sales Outstanding	275.72
Days Payables Outstanding	745.68	1.22K
Days Inventory Outstanding	9.81
Operating Cycle	823.59	11.67K
Cash Conversion Cycle	776.31	11.39K
Asset Turnover	0.53	0.01

Metric
Operating Cash Flow	-5.23M	-2.02M
Free Cash Flow	-5.39M	-2.24M
Cash Flow to Debt	-0.46	-1.47
Operating Cash Flow/Sales	-1.27	-3.59
Free Cash Flow Yield	-0.11	-0.00

Metric
Cash & Equivalents	13.69M	936.97K
Accounts Receivable	1.23M
Inventory	287.29K
Goodwill
Debt to Capitalization	2.81	0.06
Debt to Assets	1.08	0.02
Current Ratio	1.05	2.32
Quick Ratio	1.01	1.34

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue